Application No.: 09/754,347

Attorney Docket No.: XMP 2037

REMARKS/ARGUMENTS

Applicant acknowledges receipt of the Office Action dated June 30, 2003. Claims 1-7, 9-

49, 54-60, 62-102, and 107-115 have been cancelled in response to this action. New claims 116-

143 are presented herein. All new claims are supported in the specification as originally filed; no

new matter has been incorporated. Claims 116-143 remain in the case. Reconsideration and

further examination of the application is respectfully requested.

The examiner has rejected Claims 1-6, 54-59, 103-106, and 113-115 under 35 USC

103(a) as unpatentable over Wiersma, Hamel, Ayer, and Weinstein, combined with Armstrong.

Wiersma, Hamel, Ayer and Weinstein are described by the examiner as "essentially duplicative"

references which teach anti-histamines, alone or in combination with a decongestant, for

treatment of allergies. Armstrong shows stinging nettle in a composition intended for treatment

of allergies. The examiner asserts that it would have been obvious to one of ordinary skill in the

art to combine stinging nettle with other allergy-treating drugs.

Similarly, the examiner has rejected Claims 107-109 under 35 USC 103(a) as

unpatentable over Wiersma, Hamel, Ayer, and Weinstein combined with Armstrong, and further

in view of Thomas, on the grounds that Thomas provides motivation to add milk thistle to the

claimed composition.

Also, the examiner has rejected Claims 1107-109 under 35 USC 103(a) as unpatentable

over Wiersma, Hamel, Ayer, and Weinstein combined with Armstrong, and further in view of

Bryce-Smith, on the grounds that Bryce-Smith teaches that zinc is an effective immune booster,

and that it would have been obvious to one of ordinary skill in the art to combine zinc with other

allergy treating agents.

-8-

Application No.: 09/754,347

Attorney Docket No.: XMP 2037

However, a review of Armstrong, a key reference used in each of the above rejections,

shows that the primary active ingredient in the treatment regimen described is cyanocobalamin

(Vitamin B12), a biochemical that contains a tetrapyrrole ring system that is chemically very

similar to the porphyrin ring system of the heme compounds. This vitamin is not available from

plant sources. Armstrong further says that stinging nettle may be administered along with

cyanocobalamin.

However, Armstrong fails to provide any teaching that would lead one of ordinary skill in

the art to substitute the combination of stinging nettle and an anti-histamine for a

cyanocobalamin/stinging nettle regimen for treatment of allergies. Similarly, Wiersma, Hamel,

Ayer and Weinstein fail to provide a teaching that would lead one of ordinary skill in the art to

compound the disclosed antihistamines with stinging nettle.

Thus, newly presented independent claims 116 and 126-129 have been drafted so as to

restrict the neutraceutical component of the claimed composition to be stinging nettle or an

extract thereof; and optionally, a second neutraceutical, where the second neutraceutical may be

a herb or herb extract, zinc or a compound thereof, and/or ascorbic acid or a salt or a derivative

thereof. Cyanocobalamin, the essential component in the treatment regimen of Armstrong, is

explicitly excluded from these claims, since cyanocobalamin is exclusively derived from animal

sources.

While we believe that the instant amendment places the application in condition for

allowance, should the Examiner have any further comments or suggestions, it is respectfully

requested that the Examiner telephone the undersigned attorney in order to expeditiously resolve

any outstanding issues.

- 9 -

Application No.: 09/754,347 Attorney Docket No.: XMP 2037

In the event that the fees submitted prove to be insufficient in connection with the filing of this paper, please charge our Deposit Account Number 50-0578 and please credit any excess fees to such Deposit Account.

Respectfully submitted, KRAMER & AMADO, P.C.

Thomas A. Powers

Registration No: 38,582

KRAMER & AMADO, P.C. Crystal Plaza One 2001 Jefferson Davis Highway Suite 1101 Arlington, VA 22202

Date.